The NINDS Parkinson's disease biomarkers program: The Ninds Parkinson's Disease Biomarkers Program

Journal Article · Wed Oct 07 04:00:00 EDT 2015 · Movement Disorders

DOI:https://doi.org/10.1002/mds.26438· OSTI ID:1347880

Rosenthal, Liana S. ^[1]; Drake, Daniel ^[2]; Alcalay, Roy N. ^[3]; Babcock, Debra ^[4]; Bowman, F. DuBois ^[2]; Chen-Plotkin, Alice ^[5]; Dawson, Ted M. ^[6]; Dewey, Richard B. ^[7]; German, Dwight C. ^[8]; Huang, Xuemei ^[9]; Landin, Barry ^[10]; McAuliffe, Matthew ^[10]; Petyuk, Vladislav A. ^[11]; Scherzer, Clemens R. ^[12]; Hillaire-Clarke, Coryse St. ^[4]; Sieber, Beth-Anne ^[4]; Sutherland, Margaret ^[4]; Tarn, Chi ^[13]; West, Andrew ^[14]; Vaillancourt, David ^[15] ; Zhang, Jing ^[16]; Gwinn, Katrina ^[4]

---

1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore Maryland USA
2. Department of Biostatistics, Columbia University, New York New York USA
3. Department of Neurology, Columbia University, New York New York USA
4. National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda Maryland USA
5. Department of Neurology, University of Pennsylvania, Philadelphia Pennsylvania USA
6. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore Maryland USA; Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Solomon H. Snyder Department of Neuroscience, Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore Maryland USA
7. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas USA
8. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas USA
9. Department of Neurology, Penn State Hershey Medical Center, Hershey Pennsylvania USA
10. Center for Information Technology, National Institutes of Health, Bethesda Maryland USA
11. Biological Sciences Division, Pacific Northwest National Laboratory, Richland Washington USA
12. Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Cambridge Massachusetts USA
13. Coriell Institute for Medical Research, Camden New Jersey USA
14. Department of Neurology, University of Alabama at Birmingham, Birmingham USA
15. Department of Applied Physiology and Kinesiology, University of Florida, Gainesville Florida USA
16. Department of Pathology, University of Washington, Seattle Washington USA

Background: Neuroprotection for Parkinson Disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke (NINDS) has therefore established the Parkinson’s Disease Biomarkers Program (PDBP) to promote discovery of biomarkers for use in phase II-III clinical trials in PD. Methods: The PDBP facilitates biomarker development to improve neuroprotective clinical trial design, essential for advancing therapeutics for PD. To date, eleven consortium projects in the PDBP are focused on the development of clinical and laboratory-based PD biomarkers for diagnosis, progression tracking, and/or the prediction of prognosis. Seven of these projects also provide detailed longitudinal data and biospecimens from PD patients and controls, as a resource for all PD researchers. Standardized operating procedures and pooled reference samples have been created in order to allow cross-project comparisons and assessment of batch effects. A web-based Data Management Resource facilitates rapid sharing of data and biosamples across the entire PD research community for additional biomarker projects. Results: Here we describe the PDBP, highlight standard operating procedures for the collection of biospecimens and data, and provide an interim report with quality control analysis on the first 1082 participants and 1033 samples with quality control analysis collected as of October 2014. Conclusions: By making samples and data available to academics and industry, encouraging the adoption of existing standards, and providing a resource which complements existing programs, the PDBP will accelerate the pace of PD biomarker research, with the goal of improving diagnostic methods and treatment.

• Research Organization: Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
• Sponsoring Organization: USDOE
• Contributing Organization: on behalf of the PDBP consortium
• DOE Contract Number: AC05-76RL01830
• OSTI ID: 1347880
• Report Number(s): PNNL-SA-110383; 47790; 400412000
• Journal Information: Movement Disorders, Journal Name: Movement Disorders Journal Issue: 6 Vol. 31; ISSN 0885-3185
• Country of Publication: United States
• Language: English

Related Subjects

Environmental Molecular Sciences Laboratory
Parkinsonism
biofluids
data management
disease-modifying strategies